Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178178 | 0.95 | ACLY (0.43) | CCR1ACLYKMT2AMEN1USP5 | |
| SCHEMBL4180784 | 0.92 | CCR1 (0.46) | CCR1ACLYKMT2AMEN1USP5 | |
| SCHEMBL4191798 | 0.89 | CCR1 (0.51) | CCR1KMT2AMEN1USP5POLB | |
| SCHEMBL4180506 | 0.87 | ACLY (0.45) | ACLYKMT2AMEN1USP5RAB9A | |
| SCHEMBL4179292 | 0.87 | TRPV4 (0.51) | CCR1ACLYKMT2AMEN1TRPV4 | |
| SCHEMBL4181177 | 0.87 | KMT2A (0.39) | CCR1ACLYKMT2AMEN1POLB | |
| SCHEMBL4187937 | 0.86 | CNR1 (0.43) | ACLYKMT2AMEN1RAB9ACNR1 | |
| SCHEMBL4178660 | 0.84 | SMN1; SMN2 (0.40) | ACLYKMT2AMEN1RAB9APOLB | |
| SCHEMBL4183423 | 0.84 | KMT2A (0.46) | CCR1KMT2AMEN1USP5POLB | |
| SCHEMBL4185927 | 0.84 | KMT2A (0.43) | ACLYKMT2AMEN1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | CCR1 283/4885ACLY 4455/4885KMT2A 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.